Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker HRTX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | PK and Safety After C-Section NCT03955211 · Postoperative Pain HTX-011, ZYNRELEF kit components for administration | HRTX Heron Therapeutics | Phase 2 | Completed | 25 | Dec 3, 2021 | Registry ↗ |
| Oct 28, 2026 | Cohort 2 (Abdominoplasty) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011) NCT06109428 · Postoperative Pain, Abdominoplasty Surgery MMA regimen, ZYNRELEF kit components for administration | HRTX Heron Therapeutics | Phase 4 | Completed | 37 | Mar 29, 2022 | Registry ↗ |
| Oct 28, 2026 | Bupivacaine HCl PK and Safety in Augmentation Mammoplasty NCT03705065 · Postoperative Pain Bupivacaine HCl | HRTX Heron Therapeutics | Phase 4 | Completed | 30 | Oct 8, 2018 | Registry ↗ |
| Oct 27, 2026 | Cohort 1 (TSA) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011) NCT06109415 · Postoperative Pain, Total Shoulder Arthroplasty HTX-011, Bupivacaine Hydrochloride | HRTX Heron Therapeutics | Phase 4 | Completed | 30 | Jul 18, 2022 | Registry ↗ |
| Jul 17, 2026 | HTX-011 for Post-bunionectomy Analgesia NCT02471898 · Analgesia HTX-011, Placebo | HRTX Heron Therapeutics | Phase 2 | Completed | 71 | Sep 2015 | Registry ↗ |
| Jun 9, 2026 | Dose-Escalation Study of HTX-034 Following Bunionectomy NCT04398329 · Bunions, Postoperative Pain HTX-034 low dose, HTX-034 high dose | HRTX Heron Therapeutics | Phase 1/2 | Completed | 78 | Jul 15, 2021 | Registry ↗ |
| Jun 4, 2026 | Study of Post-Herniorrhaphy Non-opioid MMA Regimens NCT03907176 · Analgesia HTX-011, Luer lock applicator | HRTX Heron Therapeutics | Phase 3 | Completed | 209 | Oct 25, 2021 | Registry ↗ |
| May 12, 2026 | Pediatric Postoperative Analgesia Herniorrhaphy Study NCT03922048 · Analgesia HTX-011, Bupivacaine HCl | HRTX Heron Therapeutics | Phase 2 | Withdrawn | 0 | Nov 2025 | Registry ↗ |
| Mar 2, 2026 | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) NCT04470622 · COVID-19 Aprepitant injectable emulsion, Saline Placebo | HRTX Heron Therapeutics | Phase 2 | Terminated | 27 | Apr 9, 2021 | Registry ↗ |
| Mar 2, 2026 | Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen NCT03974932 · Analgesia HTX-011, Ibuprofen | HRTX Heron Therapeutics | Phase 3 | Completed | 116 | Dec 7, 2020 | Registry ↗ |
| Mar 2, 2026 | Phase 2 Bunionectomy HTX-011 Administration Study NCT03718039 · Postoperative Pain HTX-011, Luer Lock applicator | HRTX Heron Therapeutics | Phase 2 | Completed | 78 | Jan 31, 2019 | Registry ↗ |
| Mar 2, 2026 | Phase 2 Herniorrhaphy Study for Opioid Elimination NCT03695367 · Postoperative Pain HTX-011, Luer lock applicator | HRTX Heron Therapeutics | Phase 2 | Completed | 63 | Nov 20, 2018 | Registry ↗ |
| Mar 2, 2026 | Bunionectomy Study for Postoperative Analgesia (EPOCH 1) NCT03295721 · Postoperative Pain HTX-011, Saline Placebo | HRTX Heron Therapeutics | Phase 3 | Completed | 412 | Jan 8, 2018 | Registry ↗ |
| Mar 2, 2026 | Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2) NCT03237481 · Postoperative Pain HTX-011, Bupivacaine HCl | HRTX Heron Therapeutics | Phase 3 | Completed | 418 | Dec 22, 2017 | Registry ↗ |
| Mar 2, 2026 | Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia NCT03015532 · Postoperative Pain HTX-011, Saline Placebo | HRTX Heron Therapeutics | Phase 2 | Completed | 285 | Apr 20, 2018 | Registry ↗ |
| Mar 2, 2026 | Phase 2B Upper Extremity Nerve Block Study NCT03011333 · Postoperative Pain HTX-011, Bupivacaine HCl without epinephrine | HRTX Heron Therapeutics | Phase 2 | Completed | 243 | Feb 1, 2018 | Registry ↗ |
| Mar 2, 2026 | Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplas… NCT02689258 · Postoperative Pain HTX-011B, Placebo | HRTX Heron Therapeutics | Phase 2 | Completed | 277 | Mar 2017 | Registry ↗ |
| Mar 2, 2026 | Pilot Herniorrhaphy Study for Postoperative Analgesia NCT02504580 · Postoperative Pain HTX-011, Placebo | HRTX Heron Therapeutics | Phase 2 | Completed | 463 | Mar 2017 | Registry ↗ |
| Mar 2, 2026 | A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Rec… NCT02106494 · Chemotherapy-induced Nausea and Vomiting APF530, Ondansetron | HRTX Heron Therapeutics | Phase 3 | Completed | 942 | May 2015 | Registry ↗ |
| Mar 2, 2026 | APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and V… NCT00343460 · Nausea and Vomiting, Unspecified Adult Solid Tumor, Protoco… APF530, dexamethasone | HRTX Heron Therapeutics | Phase 3 | Completed | 1,428 | Sep 2008 | Registry ↗ |
| Feb 23, 2026 | Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia F… NCT02762929 · Postoperative Pain, Bunions HTX-011A, Saline Placebo | HRTX Heron Therapeutics | Phase 2 | Completed | 430 | Feb 2017 | Registry ↗ |
| Feb 12, 2026 | A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin NCT01416259 · Healthy Withdraw treatment | HRTX Heron Therapeutics | — | Completed | 56 | Oct 2011 | Registry ↗ |
| Oct 26, 2023 | A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401. NCT05109312 · Analgesia Bupivacaine Hydrochloride, Bupivacaine Hydrochloride | HRTX Heron Therapeutics | Phase 4 | Active, not recruiting | 90 | Jun 2024 | Registry ↗ |
| Jul 28, 2023 | Safety Study of Repeat Doses of SUSTOL in Adults NCT05434663 · Chemotherapy-Induced Nausea and Vomiting (CINV) SUSTOL | HRTX Heron Therapeutics | Phase 4 | Active, not recruiting | 300 | Oct 2025 | Registry ↗ |
| Jun 12, 2023 | HTX-011 in Spinal Surgery NCT04911062 · Post-Operative Pain, Lumbar Laminectomy Bupivacaine HCI without epinephrine, HTX-011 | HRTX Heron Therapeutics | Phase 2 | Completed | 32 | Jul 29, 2022 | Registry ↗ |
| Sep 26, 2019 | Extended Delivery of Bupivacaine Study in Herniorrhaphy NCT04102267 · Analgesia Bupivacaine liposome injectable suspension, Bupivacaine HCl… | HRTX Heron Therapeutics | Phase 4 | Completed | 32 | Sep 3, 2018 | Registry ↗ |
26 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:51 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances